All
Guest Commentary: Skin disease comorbidities: Understanding simultaneous disorders
February 1st 2009On Oct. 15, 2008, the Society for Investigative Dermatology (SID) sponsored a comorbidities conference in Bethesda, Md. This event was the first of what is projected to be a multi-year series of meetings that aim to explore our knowledge base of comorbid states that exist in association with skin disease.
Down but not out: Aesthetic market tightens with bankruptcies, buyouts
February 1st 2009National report - The bankruptcy of Artes Medical, maker of the permanent facial filler ArteFill, will make it harder for permanent fillers to enter the U.S. market in the future, analysts say - although one such product, Contura's Aquamid, will likely seek Food and Drug Administration (FDA) approval in 2009.
How the New President and Congress Will Financially Impact YOU in 2009
January 14th 2009After an historic turnout for a Barack Obama landslide victory and a stronger democratic majority in both the house and senate, the table is set to allow the democrats to make every attempt to address the issues facing our country.
Laying the groundwork: Researchers prepare for $1.6 million study to improve wound healing
January 6th 2009Norfolk, Va. - Researchers at Old Dominion University (ODU) in Norfolk, Va., are gearing up to begin work on a $1.6 million study to learn how tiny pulses of electricity can reduce wound-related infections and accelerate the healing process.
Immunizing against skin cancer: Novel vaccine could be on the horizon
January 1st 2009Brisbane, Australia Early results of animal studies suggest that a vaccine for some types of skin cancer in humans may be available in five to 10 years, according to Ian Frazer, M.D., an Australian scientist who helped develop the Gardasil (Merck) vaccine for cervical cancer.
Diagnostic imaging: State-of-the-art techniques advance ability to detect melanoma
January 1st 2009The future of melanoma diagnosis will involve increasingly sophisticated devices such as multispectral digital dermoscopy, confocal laser scanning microscopy and perhaps optical frequency domain imaging, an expert says.
Feeling the pinch: Economy squeezes Aesthetic bookings; proactive push helps derms stay busy
January 1st 2009National report - The precarious U.S. economy has slashed patient spending on Aesthetic treatments, and some dermatologists say medical bookings also have declined since the stock market plummeted in the closing months of 2008.
Safety check: FDA panel: Dermal filler warnings necessary for public
January 1st 2009Washington - Dermatologists and manufacturers say dermal fillers are safe and effective, despite a recent recommendation by a Food and Drug Administration (FDA) advisory panel that labeling be revised to include stronger warnings about possible complications.
S corp or C corp?: Maximize tax deductions by using both structures for your medical practice
January 1st 2009Choosing the form and structure of one's medical practice is an important decision. Most advisers to medical practices believe that the avoidance of potential double taxation makes the S corporation the logical choice. This "conventional wisdom" overlooks the potential benefits a C corporation can offer.
Medicare 101: Examine 2009 update for effect on practice
January 1st 2009"In July 2008, we were elated to learn that Congress had reversed the 10.6 percent cut in the Medicare conversion factor scheduled for the second half of that year. Even better, Congress added a 1.1 percent increase - in lieu of the mandated 15.1 percent cut - for 2009 in the Medicare Improvement for Patients and Providers Act of 2008 (MIPPA). "
Leiomyosarcoma: Rare soft tissue tumor could have grave repercussions if diagnosis is missed
January 1st 2009Leiomyosarcoma (LMS) is a very rare soft tissue tumor; however, if the diagnosis is missed, repercussions can be grave, reflected in a poor prognosis. Clinicians should be aware of the cutaneous variant and, although LMS is rare, it should be considered in the differential diagnosis of obscure and ambiguous presenting tumors.
Resistant psoriasis: Lifelong therapies increase risks for cutaneous malignancies
January 1st 2009Psoriasis patients treated for many years with PUVA therapy may be more susceptible to develop cutaneous carcinomas, such as basal cell carcinoma, especially when combined with short regimens of cyclosporine A. Physicians who must turn to this combination regimen in therapy-resistant psoriasis patients should be aware of the possible increased risk for the development of skin cancers in these patients.